text_1: Lilly diabetes drug slashes deaths 32 pct in heart-risk patients
text_2: This Reuters story summarizes new findings about Jardiance (empaglifozin), a diabetes drug developed by Eli Lilly and Boehringer Ingelheim and approved by the FDA last year. Following a recently published study, Jardiance is now being positioned as an add-on to standard care and a preventative therapy that reduces the risk of cardiovascular death, as well as risk of death from any cause, in patients with type 2 diabetes. The story capably lays out the basics of the study, but its reliance on relative risk figures (which may tend to inflate the magnitude of the effect), as well as the lack of any comment on potential harms, were considered significant drawbacks by our reviewers. Editor’s note: We learned that Reuters made updates to the initial version of this story, including the headline, after our review was complete. Although we applaud such efforts to provide more information and context to readers, such efforts do miss readers like us who only saw the original version of the story. People with type 2 diabetes are two to four times more likely to develop cardiovascular disease than people without diabetes, according to the World Heart Association. Cardiovascular disease is also a leading cause of death among people with diabetes. An add-on therapy that can help prevent serious heart disease and fatal complications could have a significant impact on the lives of millions of people with type 2 diabetes.The CDC estimates that more than 9% of the U.S. population — or 29 million people — have type 2 diabetes.